Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
AstraZeneca
Moodys
Dow
Merck

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Aspartame

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Aspartame?

Aspartame is an investigational drug.

There have been 5 clinical trials for Aspartame. The most recent clinical trial was a Phase 2 trial, which was initiated on March 8th 2019.

The most common disease conditions in clinical trials are Diabetes Mellitus, Kidney Diseases, and Diabetic Nephropathies. The leading clinical trial sponsors are Universal Integrated Corp., Singapore General Hospital, and National Medical Research Council (NMRC), Singapore.

There are eight hundred and ninety-five US patents protecting this investigational drug and ten international patents.

Recent Clinical Trials for Aspartame
TitleSponsorPhase
Study of the Efficacy and Safety of Quiklean® and Klean-Prep With Dulcolax® for the Bowel Preparation Prior to ColonoscopyUniversal Integrated Corp.Phase 3
Effects of Fenofibrate Therapy in Diabetic NephropathyNational Medical Research Council (NMRC), SingaporePhase 3
Effects of Fenofibrate Therapy in Diabetic NephropathySingapore General HospitalPhase 3

See all Aspartame clinical trials

Clinical Trial Summary for Aspartame

Top disease conditions for Aspartame
Top clinical trial sponsors for Aspartame

See all Aspartame clinical trials

US Patents for Aspartame

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Aspartame   Start Trial Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same Protalix Ltd. (Carmiel, IL)   Start Trial
Aspartame   Start Trial Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA)   Start Trial
Aspartame   Start Trial Steviol glucosyltransferases and genes encoding the same SUNTORY HOLDINGS LIMITED (Osaka, JP)   Start Trial
Aspartame   Start Trial Granulation of a stevia sweetener PureCircle Sdn Bhd (Kuala Lumpur, MY)   Start Trial
Aspartame   Start Trial Orally disintegrable tablet Takeda Pharmaceuticals Company Limited (Osaka, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Aspartame

Drugname Country Document Number Estimated Expiration Related US Patent
Aspartame Australia 2006269422 2025-07-07   Start Trial
Aspartame Canada 2614436 2025-07-07   Start Trial
Aspartame European Patent Office 1917020 2025-07-07   Start Trial
Aspartame European Patent Office 2722051 2025-07-07   Start Trial
Aspartame European Patent Office 3498289 2025-07-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Express Scripts
Dow
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.